Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma

A method of treating multiple myeloma comprising administering to a patient in need of such treatment a therapeutically effective amount of

• a) a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CDR (CD3), wherein said first binding part comprises:
• a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR1L region of SEQ ID NO:27, a CDR2L region of SEQ ID NO:28 and a CDR3L region of SEQ ID NO:20;
• and,
• b) an immunotherapeutic drug selected from the group consisting of thalidomide or an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody;
• wherein the bispecific antibody and the immunotherapeutic drug are administered separately or together.